XML 58 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Our product sales consist of the following (in millions):
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Antiviral products:
 
 
 
 
 
 
Harvoni
 
$
4,370

 
$
9,081

 
$
13,864

Genvoya
 
3,674

 
1,484

 
45

Epclusa
 
3,510

 
1,752

 

Truvada
 
3,134

 
3,566

 
3,459

Atripla
 
1,806

 
2,605

 
3,134

Descovy
 
1,218

 
298

 

Stribild
 
1,053

 
1,914

 
1,825

Viread
 
1,046

 
1,186

 
1,108

Odefsey
 
1,106

 
329

 

Complera/Eviplera
 
966

 
1,457

 
1,427

Sovaldi
 
964

 
4,001

 
5,276

Vosevi
 
293

 

 

Other antiviral
 
196

 
72

 
69

Total antiviral products
 
23,336

 
27,745

 
30,207

Other products:
 
 
 
 
 
 
Letairis
 
887

 
819

 
700

Ranexa
 
717

 
677

 
588

AmBisome
 
366

 
356

 
350

Zydelig
 
149

 
168

 
132

Other products
 
207

 
188

 
174

Total product sales
 
$
25,662

 
$
29,953

 
$
32,151

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area
The following table summarizes total revenues from external customers and collaboration partners by geographic region (in millions). Product sales and product-related contract revenue are attributed to regions based on ship-to location. Royalty and non-product related contract revenue are attributed to regions based on the location of the collaboration partner.
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
Revenues:
 
 
 
 
 
 
United States
 
$
18,194

 
$
19,354

 
$
21,234

Europe
 
5,311

 
6,365

 
7,528

Other countries
 
2,602

 
4,671

 
3,877

Total revenues
 
$
26,107

 
$
30,390

 
$
32,639

Schedule of Revenue by Major Customers
The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):
 
 
Year Ended December 31,
 
 
2017
 
2016
 
2015
McKesson Corp.
 
23
%
 
22
%
 
24
%
AmerisourceBergen Corp.
 
20
%
 
18
%
 
19
%
Cardinal Health, Inc.
 
19
%
 
16
%
 
15
%